featured
Adverse Effect Profile for Tivozanib Plus Sorafenib for Relapsed/Refractory Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: